Following a highly anticipated regulatory update from federal health officials, shares of leading inpatient rehabilitation providers are seeing a significant lift. The Centers for Medicare & Medicaid Services (CMS) has proposed a more generous payment rate increase than many analysts had initially modeled, signaling a stable reimbursement environment for the coming fiscal year. Encompass Health (NYSE: EHC) has emerged as the primary beneficiary of this news, with its stock trending higher as investors digest the implications of the multi-million dollar tailwind.

The CMS announcement, which outlines the Inpatient Rehabilitation Facility (IRF) Prospective Payment System (PPS) proposed rule for Fiscal Year 2027, suggests a total increase in payments of 2.8% for the industry. For a "pure-play" operator like Encompass Health, which derives the vast majority of its revenue from these specialized services, the update provides crucial visibility into its margin profile for the next eighteen months. Market participants are viewing the proposal as a "status quo plus" outcome, especially given the historical pressure from advisory bodies to limit payment growth in the post-acute care sector.

Breaking Down the CMS FY 2027 Proposed Rule

The proposed rule, designated as CMS-1845-P, was officially released on April 2, 2026, marking a pivotal moment in the annual regulatory cycle for healthcare providers. At the heart of the update is a 2.4% net payment update, which is derived from a 3.2% market basket increase minus a federally mandated 0.8% productivity adjustment. However, when factoring in technical adjustments to "outlier" thresholds—payments designed to cover exceptionally high-cost cases—the total estimated impact rises to a 2.8% increase, or approximately $355 million in additional funding for the nation’s 1,100 inpatient rehab facilities.

This timeline is consistent with CMS’s usual spring release schedule, but the 2027 proposal carries extra weight due to new operational mandates. Specifically, CMS is moving to strictly enforce the "36-hour rule," which requires that all intensive therapies (physical, occupational, and speech) begin within 36 hours of the day of admission. Additionally, the rule proposes tightening the window for interdisciplinary team meetings, requiring them to occur no later than the fourth day of a patient’s stay. These changes are designed to ensure that the "intensive" nature of IRF care is justified by immediate and coordinated clinical action.

Initial market reaction was measured but has since turned decidedly bullish as institutional investors analyzed the sub-surface details. While the base percentage is slightly lower than the 3.3% market basket seen in the FY 2026 rule, the reduction in the outlier threshold from $10,062 to $8,689 is a significant win. By lowering the "entry fee" for outlier payments, CMS is effectively allowing more complex, high-acuity cases to qualify for extra reimbursement—a shift that plays directly into the hands of large, sophisticated operators who handle the most difficult patient populations.

Winners and Losers in the Post-Acute Landscape

Encompass Health (NYSE: EHC) stands at the top of the winners' circle. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, with a market share of roughly 22% of Medicare IRF discharges, the company is expected to capture nearly $80 million of the proposed $355 million industry-wide increase. EHC's scale allows it to absorb the administrative costs of the new 36-hour therapy mandate more efficiently than smaller, independent facilities. Its robust "hub and spoke" development strategy and focus on de novo (new build) hospitals are perfectly positioned to capitalize on a stable reimbursement floor.

Select Medical Holdings (NYSE: SEM) is also poised to benefit, though its impact is more diluted due to its diversified business model, which includes outpatient clinics and critical illness recovery hospitals. Nevertheless, its Inpatient Rehabilitation division, which operates 38 hospitals, will see a similar per-facility boost. Interestingly, the CMS news comes as Select Medical is reportedly weighing a take-private proposal from its leadership, potentially adding another layer of valuation support to the stock. Private players like ScionHealth and PAM Health are also expected to see improved valuations, which could drive further M&A activity in the private equity space as they look to exit or roll up smaller competitors.

On the other side of the ledger, the "losers" may include smaller, rural facilities that are entering the third and final year of a phase-out for the 14.9% rural adjustment. As this extra funding disappears, these smaller hospitals may struggle to meet the new, more stringent documentation and therapy timeline requirements. Furthermore, managed care organizations and private insurers often follow Medicare’s lead; however, the increased rates for providers mean higher costs for payers who may lack the leverage to negotiate these rates down in an environment where IRF bed capacity remains tight.

A Strategic Shift in Regulatory Winds

The FY 2027 proposed rule is significant not just for the dollars it provides, but for what it says about the broader regulatory philosophy toward post-acute care. For years, the Medicare Payment Advisory Commission (MedPAC) has recommended that CMS keep IRF payments flat or even reduce them, arguing that the sector enjoys high margins. By choosing to ignore these recommendations and provide a 2.8% total impact boost, CMS is tacitly acknowledging the critical role these facilities play in reducing hospital readmissions and managing the "silver tsunami" of an aging American population.

This event fits into a wider industry trend of "site-of-service" shifts. As traditional acute-care hospitals face overcrowding, there is a systemic push to move patients into specialized settings like IRFs more quickly. The 36-hour therapy rule is a regulatory "stick" to ensure that these facilities are not merely acting as holding pens but are providing the high-intensity medical rehab they are paid for. This aligns with the long-term goal of the "unified post-acute care payment model," which seeks to eventually pay for patient outcomes rather than the specific type of building the patient is in.

Historically, IRF stocks have been sensitive to these annual updates. In years where the update fell below 2%, the sector often traded sideways or down. The 2026/2027 cycle represents a period of surprising resilience for the sector’s reimbursement. This stability provides a green light for companies to continue their aggressive capital expenditure plans, building new hospitals in high-growth markets like the Sun Belt, where the demand for post-stroke and orthopedic rehabilitation is skyrocketing.

The Path Forward: Strategy and Adaptation

In the short term, Encompass Health and its peers will spend the next 60 days in a public comment period, likely lobbying CMS to further refine the 36-hour rule to allow for clinical exceptions. The final rule is expected in late July or early August 2026, with the new rates taking effect on October 1, 2026. Investors should watch for any changes in the "outlier threshold" in the final version, as this was the hidden gem of the proposed rule that drove the total impact higher.

Longer-term, the focus will shift to how these companies adapt to the Request for Information (RFI) included in the proposal regarding "Modernizing the IRF PPS." CMS is signaling that it wants to move toward a diagnosis-based classification system, similar to what was recently implemented in Skilled Nursing Facilities. This would be a massive structural change. Strategic pivots may include even heavier investments in data analytics and electronic health records to ensure that every patient’s functional status is perfectly documented to maximize payment under a future, more complex system.

The emergence of "small-format" hospitals—a strategy Encompass Health is slated to expand in 2027—will likely be a key battleground. These smaller, 30-to-40 bed facilities allow for quicker entry into suburban markets and may be more agile in meeting the new 36-hour and 4-day meeting requirements compared to aging, 100-bed legacy institutions.

Summary and Investor Outlook

The CMS FY 2027 proposed rule is a clear win for the inpatient rehabilitation sector, providing a 2.8% total payment lift that exceeds conservative market expectations. For Encompass Health (NYSE: EHC), the news reaffirms its position as a high-conviction growth story in the healthcare services space. The combination of a lower outlier threshold and a healthy market basket update provides the financial oxygen needed to fuel the company’s ambitious hospital expansion plans.

Moving forward, the market will likely reward operators who can demonstrate "compliance at scale"—the ability to meet the new, faster therapy initiation and interdisciplinary meeting timelines without ballooning labor costs. The labor market remains the primary risk; while reimbursement is rising, it must stay ahead of nursing and therapist wage inflation to maintain current margins.

Investors should keep a close eye on the final rule release this summer and monitor the progress of EHC’s de novo pipeline. If the company can maintain its current discharge growth while capturing these higher Medicare rates, the upward trajectory for the stock likely has significant room to run. The era of regulatory uncertainty that once haunted the post-acute space appears, for now, to have been replaced by a period of predictable, inflation-aligned growth.

This content is intended for informational purposes only and is not financial advice.